Cardiotoxicity of Oncologic Treatments / / edited by Manuela Fiuza.
The possibility of getting a cardiovascular disease or cancer increases with advancing age. At the same time, relevant improvements in cancer therapy have resulted in the improvement of quality of life and the increasement of the survival rate of such patients. As a result we have larger number of p...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | Rijeka : : InTech,, 2012. ©2012 |
| Year of Publication: | 2012 |
| Language: | English |
| Physical Description: | 1 online resource (xi, 196 pages) :; illustrations |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993547250304498 |
|---|---|
| ctrlnum |
(CKB)3230000000075734 (NjHacI)993230000000075734 (oapen)https://directory.doabooks.org/handle/20.500.12854/65912 (EXLCZ)993230000000075734 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Fiuza, Manuela edt Cardiotoxicity of Oncologic Treatments / edited by Manuela Fiuza. IntechOpen 2012 Rijeka : InTech, 2012. ©2012 1 online resource (xi, 196 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on: online resource; title from PDF information screen (InTech, viewed October 23, 2022). Includes bibliographical references. The possibility of getting a cardiovascular disease or cancer increases with advancing age. At the same time, relevant improvements in cancer therapy have resulted in the improvement of quality of life and the increasement of the survival rate of such patients. As a result we have larger number of patients that experience the cardiac side effects of chemotherapy. The extent of cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, prior mediastinal radiotherapy and the presence of cardiovascular risk factors or history of heart disease. Early detection of the patients proneness for developing cardiotoxicity is the key issue to decrease morbidity and mortality. It also facilitates more tailored therapeutic interventions. Therefore, the collaboration and interaction of cardiology and oncology may contribute to reducing the cardiovascular adverse effects and improving the results in the treatment of patients with cancer. English Cancer Treatment. Cardiovascular medicine 953-51-0273-7 Fiúza, Manuela, editor. |
| language |
English |
| format |
eBook |
| author2 |
Fiúza, Manuela, |
| author_facet |
Fiúza, Manuela, |
| author2_variant |
m f mf m f mf |
| author2_role |
TeilnehmendeR |
| title |
Cardiotoxicity of Oncologic Treatments / |
| spellingShingle |
Cardiotoxicity of Oncologic Treatments / |
| title_full |
Cardiotoxicity of Oncologic Treatments / edited by Manuela Fiuza. |
| title_fullStr |
Cardiotoxicity of Oncologic Treatments / edited by Manuela Fiuza. |
| title_full_unstemmed |
Cardiotoxicity of Oncologic Treatments / edited by Manuela Fiuza. |
| title_auth |
Cardiotoxicity of Oncologic Treatments / |
| title_new |
Cardiotoxicity of Oncologic Treatments / |
| title_sort |
cardiotoxicity of oncologic treatments / |
| publisher |
IntechOpen InTech, |
| publishDate |
2012 |
| physical |
1 online resource (xi, 196 pages) : illustrations |
| isbn |
953-51-6893-2 953-51-0273-7 |
| callnumber-first |
R - Medicine |
| callnumber-subject |
RC - Internal Medicine |
| callnumber-label |
RC270 |
| callnumber-sort |
RC 3270.8 C373 42012 |
| illustrated |
Illustrated |
| dewey-hundreds |
600 - Technology |
| dewey-tens |
610 - Medicine & health |
| dewey-ones |
616 - Diseases |
| dewey-full |
616.99406 |
| dewey-sort |
3616.99406 |
| dewey-raw |
616.99406 |
| dewey-search |
616.99406 |
| work_keys_str_mv |
AT fiuzamanuela cardiotoxicityofoncologictreatments |
| status_str |
n |
| ids_txt_mv |
(CKB)3230000000075734 (NjHacI)993230000000075734 (oapen)https://directory.doabooks.org/handle/20.500.12854/65912 (EXLCZ)993230000000075734 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Cardiotoxicity of Oncologic Treatments / |
| author2_original_writing_str_mv |
noLinkedField |
| _version_ |
1787548676359454722 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01014nam a2200301 i 4500</leader><controlfield tag="001">993547250304498</controlfield><controlfield tag="005">20221023200131.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">221023s2012 ci a ob 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">953-51-6893-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3230000000075734</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)993230000000075734</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/65912</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993230000000075734</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC270.8</subfield><subfield code="b">.C373 2012</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.99406</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fiuza, Manuela</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Cardiotoxicity of Oncologic Treatments /</subfield><subfield code="c">edited by Manuela Fiuza.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">IntechOpen</subfield><subfield code="c">2012</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Rijeka :</subfield><subfield code="b">InTech,</subfield><subfield code="c">2012.</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xi, 196 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from PDF information screen (InTech, viewed October 23, 2022).</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The possibility of getting a cardiovascular disease or cancer increases with advancing age. At the same time, relevant improvements in cancer therapy have resulted in the improvement of quality of life and the increasement of the survival rate of such patients. As a result we have larger number of patients that experience the cardiac side effects of chemotherapy. The extent of cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, prior mediastinal radiotherapy and the presence of cardiovascular risk factors or history of heart disease. Early detection of the patients proneness for developing cardiotoxicity is the key issue to decrease morbidity and mortality. It also facilitates more tailored therapeutic interventions. Therefore, the collaboration and interaction of cardiology and oncology may contribute to reducing the cardiovascular adverse effects and improving the results in the treatment of patients with cancer.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Treatment.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cardiovascular medicine</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">953-51-0273-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fiúza, Manuela,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-02-22 21:33:08 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2012-12-09 08:17:33 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338467680004498&Force_direct=true</subfield><subfield code="Z">5338467680004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338467680004498</subfield></datafield></record></collection> |